Clinical trial NCT02806856: tDCS in Acute Stroke Patients
Official title: Transcranial Direct Current Stimulation (tDCS) in Acute Stroke Patients
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Acute Stroke
Keywords: Middle Cerebral Artery Stroke
tDCS
Acute
Lead sponsor: Centre Hospitalier St Anne
Sponsor class: OTHER
Collaborators: name: Institut National de la Santé Et de la Recherche Médicale, France
First posted: 2016-06-21
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Very early after the onset of the focal perfusion deficit, excitotoxic mechanisms can lethally damage neurons and glia. Excitotoxicity triggers a number of events that can further contribute to tissue death. Such events include peri-infarct depolarizations (PID) and cortical spreading depolarization (CSD) within the peri-infarct zone or ischaemic penumbra. Noninvasive brain stimulation techniques such as transcranial direct current stimulation (tDCS) are emerging as promising tools, owing to their effects on modulating cortical activity. Experimental studies have indicated that cathodic polarization of the cortical surface blocks initiation of CSD. Moreover, it has been recently demonstrated in murine stroke models that cathodal tDCS exerts a measurable neuroprotective effect in the acute phase of stroke, decreasing the number of spreading depolarizations and reducing the infarct volume by 20 to 30%.

The investigators propose here a pilot study, in acute middle cerebral artery stroke patients, with a double blind randomization: cathodal tDCS versus sham tDCS. The duration of this study will be two years. Fifty acute middle cerebral artery stroke patients will be included. The tDCS will begin within 4.5 hours of symptom onset. The main criteria of evaluation will be the extent of diffusion-weighted imaging (DWI) infarct volume between imaging on admission and 24 hours later. The investigators propose the hypothesis that in acute stroke patients, cathodal tDCS could be an adjuvant approach to recanalizing therapies.

Detailed description: In a murine model, it has been demonstrated that a cathodic polarization of cortical surface with intensities of 30 µA and higher blocked the spreading depression completely. There is no study demonstrating this in stroke patients. tDCS is a powerful tool to modulate the excitability of motor areas. Cathodal tDCS induces a decrease of 30-50% of motor evoked potentials amplitudes. In another study, cathodal stimulation compared with sham induced a prolonged decrease of tactile discrimination, while sham stimulation did not. In our study, cathodal stimulation will be delivered over lateral motor area (C3 or C4, 10-20 system) using an intensity of 2 mA, in order to assess if an inhibition, a hyperpolarization of the middle cerebral artery stroke ischemic penumbra could be obtained.

tDCS is characterized by an excellent safety profile. tDCS studies in patients were performed with intensities comprised between 1 and 2 mA. Safety for these intensities has been demonstrated. Minor tDCS adverse effects in healthy humans and patients with varying neurological disorders were reported. These tDCS studies were performed for a wide range of neurological and psychiatric conditions including pain, depression, Parkinson disease and stroke rehabilitation. Mild tingling sensation, moderate fatigue, itching sensation under the stimulating electrodes, headache were described. Tinnitus was also reported.

In human studies, durations of tDCS stimulation are generally comprised between 3 and 40 minutes, in iterative sessions. In our study, tDCS will be begun less than 4h30 after the beginning of symptoms. Studies with murine stroke models demonstrated that cathodal tDCS starting 45 minutes after middle cerebral artery occlusion and lasting 6 hours had a neuroprotective effect reducing the infarct volume by 30% (20% in the group 4 hours of duration, compared to sham). Based on these data, in our study, tDCS will be delivered 20 minutes per hour, during 6 hours. Usual neurovascular cares (IV thrombolysis, thrombectomy if indicated) will be unchanged.

Some simulation studies have demonstrated that approximately half of the current injected during tDCS is shunted through the scalp. Using stimulating currents of 2 mA, the magnitude of the current density in relevant regions of the brain is of the order of 0.1 A/m2, corresponding to an electric field of 0.22 V/m. Induced skin burns are rare. Skin burns are preceded by a painful sensation. Saline-soaked sponges placed under the electrodes have to remain moist in order to avoid these burns. In our study, patients will be questioned about the tolerance of tDCS stimulation each hour. Impedance values of the tDCS electrodes will be checked each hour.

A cephalic electrode montage has been chosen. A setup with M1 placement of the target electrode (C3 or C4, 10-20 system) and an extra-cephalic placement of the return electrode (shoulder) leads to a twofold to threefold higher electric field in the brainstem as compared to the more commonly used cephalic setup with the target electrode over M1, and the return electrode over the contralateral fronto-polar area (FP2 or FP1, 10-20 system). Reported cerebral autoregulation changes may have been mediated via stimulation of brainstem autonomic centers. The use of a cephalic return electrode montage is thus recommended. Accordingly to these recommendations, in our study, the two electrodes are in a cephalic position: C3 or C4 and FP2 or FP1 (10-20 system).

The main objective of our study is to assess if cathodic tDCS over M1 (C3 or C4) in acute stroke patients allow to preserve the penumbra and to reduce the infarct volume (MRI day 1 versus admission MRI).

Secondary objectives are:

1. to determine if tDCS improve clinical outcome at 7 days after stroke using the National Institute of Health Stroke Scale (NIHSS)
2. to determine if tDCS improve clinical outcome at 3 months after stroke using the Rankin scale
3. To assess tDCS side effects

Eligibility criteria: Inclusion Criteria:

* age ≥ 18 years
* middle cerebral artery stroke confirmed by MRI
* neuroradiology: initial MRI with diffusion and perfusion sequences
* NIHSS scale between 4 and 25
* delay since the beginning of symptoms \< 4h30
* intravenous thrombolysis treatment
* obtained consent
* patient affiliated or benefiting from the French national insurance

Exclusion Criteria:

* pregnant woman
* contraindications for an MRI scan : heart pace-maker, patients who have a metallic foreign body (metal sliver) in their eye or in their brain.
* contraindications for the tDCS : scalp or forehead cutaneous lesion, history of intra-cranial surgery
* coma
* beginning of the symptoms cannot be precisely specified

Primary outcomes:
measure: Brain MRI diffusion weighted images
timeFrame: Day 1
Secondary outcomes:
measure: NIHSS
timeFrame: Day 7
measure: Rankin scale
timeFrame: 3 months
measure: tDCS safety
timeFrame: Each hour during 6 hours
measure: tDCS safety
timeFrame: Day 1
measure: tDCS tolerability
timeFrame: Each hour during 6 hours
measure: tDCS tolerability
timeFrame: Day 1
Other outcomes:
Locations:
city: Paris
country: France
facility: Centre Hospitalier Sainte Anne
Study officials:
affiliation: Université Paris Descartes
name: Martine GAVARET, MD, PhD
role: STUDY_DIRECTOR
affiliation: CHSA INSERM
name: Jean-Louis MAS, professor
role: PRINCIPAL_INVESTIGATOR
References: